Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424788 · ClinicalTrials.gov registry record · Early Phase 1
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
A Early Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT00424788 is a Early Phase 1 study that has completed, run by Biogen. The registered enrollment target is 12 participants.
The verdict
NCT00424788, a Early Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Natalizumab (TYSABRI) is a protein-based drug that is manufactured by Biogen Idec in partnership with Elan Pharmaceuticals. Natalizumab is approved in the US and Europe for the treatment of Multiple Sclerosis (MS). The purpose of this study is to determine whether the amount of natalizumab (TYSABRI) that is present in your blood (plasma) can be reduced or eliminated by separating and removing the plasma and replacing it with other fluids, a process called plasma exchange.
Interventions
- PROCEDURE Plasma exchange
- DRUG natalizumab treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00424788
The ClinicalTrials.gov registry entry for NCT00424788 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Plasma exchange is the first listed.
NCT00424788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00424788 about?
NCT00424788 is a clinical study titled "A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)". Natalizumab (TYSABRI) is a protein-based drug that is manufactured by Biogen Idec in partnership with Elan Pharmaceuticals. Natalizumab is approved in the US and Europe for the treatment of Multiple Sclerosis (MS). The purpose of this study is to determine whether the amount of natalizumab (TYSABRI)...
What is the current status of trial NCT00424788?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2007-01. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00424788?
The interventions under investigation include: Plasma exchange (PROCEDURE), natalizumab treatment (DRUG).
Who is sponsoring clinical trial NCT00424788?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.